Duchenne muscular dystrophy: disease mechanism and therapeutic strategies
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Duchenne muscular dystrophy (DMD) is a severe, progressive, and ultimately fatal disease of skeletal muscle wasting, respiratory insufficiency, and cardiomyopathy. The identification of the dystrophin gene as central to DMD pathogenesis has led to the understanding of the muscle membrane and the proteins involved in membrane stability as the focal point of the disease. The lessons learned from decades of research in human genetics, biochemistry, and physiology have culminated in establishing the myriad functionalities of dystrophin in striated muscle biology. Here, we review the pathophysiological basis of DMD and discuss recent progress toward the development of therapeutic strategies for DMD that are currently close to or are in human clinical trials. The first section of the review focuses on DMD and the mechanisms contributing to membrane instability, inflammation, and fibrosis. The second section discusses therapeutic strategies currently used to treat DMD. This includes a focus on outlining the strengths and limitations of approaches directed at correcting the genetic defect through dystrophin gene replacement, modification, repair, and/or a range of dystrophin-independent approaches. The final section highlights the different therapeutic strategies for DMD currently in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016) · Nature · doi:10.1038/nature17946 · Cited by 5,437 · cited 2×
“In base editing, there are two major categories of DNA base editors: cytosine base editors (CBEs), which convert the C:G base pair into a T:A base pair (Komor et al., 2016; Nishida et al., 2016; Gaudelli et al., 2017) and adenine base editors (ABEs), which convert A:T base pairs to G:C base pairs (Gaudelli et al.”
BackgroundRepurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.022 · Cited by 5,016 · cited 2×
“, 2013) and deactivated Cas9 (dCas9) (Qi et al., 2013) that have been engineered to retain their programmable DNA-binding ability while decreasing or abolishing the Cas9 endonuclease activity, respectively.”
BackgroundDystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693 · cited 3×
“Dystrophin is the connection point joining the actin cytoskeleton to the inner surface of the sarcolemma (Hoffman et al., 1987; Ahn and Kunkel, 1993).”
BackgroundProgrammable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
SATELLITE CELL OF SKELETAL MUSCLE FIBERS
Mauro, A. (1961) · The Journal of Cell Biology · doi:10.1083/jcb.9.2.493 · Cited by 3,683
TGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381 · cited 6×
“, 2019a), and clinical trials using AAV for gene replacement therapy have been approved by the FDA (Mendell et al., 2017).”
InfluentialGenome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors
Anzalone, A. V., Koblan, L. W., & Liu, D. R. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0561-9 · Cited by 2,237
Kim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667
Dystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460 · cited 1×
“Another delivery method for CRISPR components, such as RNP or mRNA/sgRNA, is via lipid-mediated nanoparticles (Zuris et al., 2015; Miller et al., 2017).”
MethodCRISPR-Cas guides the future of genetic engineering
Knott, G. J., & Doudna, J. A. (2018) · Science · doi:10.1126/science.aat5011 · Cited by 1,410
Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems
Nishida, K., Arazoe, T., Yachie, N., Banno, S., Kakimoto, M., Tabata, M., Mochizuki, M., Miyabe, A., Araki, M., Hara, K. Y., et al. (2016) · Science · doi:10.1126/science.aaf8729 · Cited by 1,349
RNA-guided gene activation by CRISPR-Cas9-based transcription factors
Perez-Pinera, P., Kocak, D. D., Vockley, C. M., Adler, A. F., Kabadi, A. M., Polstein, L. R., Thakore, P. I., Glass, K. A., Ousterout, D. G., Leong, K. W., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2600 · Cited by 1,328
A Special Population of Regulatory T Cells Potentiates Muscle Repair
Burzyn, D., Kuswanto, W., Kolodin, D., Shadrach, J. L., Cerletti, M., Jang, Y., Sefik, E., Tan, T. G., Wagers, A. J., Benoist, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.10.054 · Cited by 1,234 · cited 2×
“A distinct population of regulatory T cells (Foxp3+ Treg) drives the transition to a pro-regenerative state and potentiates muscle regeneration and repair (Burzyn et al., 2013).”
BackgroundIn vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration
Suzuki, K., Tsunekawa, Y., Hernandez-Benitez, R., Wu, J., Zhu, J., Kim, E. J., Hatanaka, F., Yamamoto, M., Araoka, T., Li, Z., et al. (2016) · Nature · doi:10.1038/nature20565 · Cited by 1,150
Regulatory interactions between muscle and the immune system during muscle regeneration
Tidball, J. G., & Villalta, S. A. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00735.2009 · Cited by 1,105 · cited 4×
“Immune cells play an important role in skeletal muscle homeostasis, repair, and regeneration (Tidball and Villalta, 2010; Castiglioni et al., 2015; Sciorati et al., 2016).”
BackgroundInfluentialIn vivo gene editing in dystrophic mouse muscle and muscle stem cells
Tabebordbar, M., Zhu, K., Cheng, J. K. W., Chew, W. L., Widrick, J. J., Yan, W. X., Maesner, C., Wu, E. Y., Xiao, R., Ran, F. A., et al. (2016) · Science · doi:10.1126/science.aad5177 · Cited by 1,046 · cited 2×
“In vitro and in vivo studies using the double-cut gene-editing approach have been used to target single-exon deletions (Maggio et al., 2016b; Long et al., 2016; Tabebordbar et al., 2016; Zhang et al., 2017; Long et al., 2018; Matre et al., 2019; Moretti et al., 2020).”
MethodDefective membrane repair in dysferlin-deficient muscular dystrophy
Bansal, D., Miyake, K., Vogel, S. S., Groh, S., Chen, C.-C., Williamson, R., McNeil, P. L., & Campbell, K. P. (2003) · Nature · doi:10.1038/nature01573 · Cited by 1,022 · cited 1×
“, 2007), and dysferlin (Bansal et al., 2003; Houang et al., 2018), all of which can negatively impact calcium cycling and muscle repair.”
BackgroundBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation
Dominguez, A. A., Lim, W. A., & Qi, L. S. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.2 · Cited by 832 · cited 4×
“This approach enables single-base transitions or transversions, as well as site-specific genomic insertions and deletions, without introducing DSBs or the need for an exogenous donor DNA as a template for HDR repair.”
BackgroundInfluentialEngineering adeno-associated viruses for clinical gene therapy
Kotterman, M. A., & Schaffer, D. V. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3742 · Cited by 761 · cited 1×
“Currently, a broad variety of AAV capsids that are either isolated from nature or engineered in laboratories have been used to accomplish systemic delivery (Townsend et al., 2007; Kotterman and Schaffer, 2014; Duan, 2016b).”
BackgroundLee, K., Conboy, M., Park, H. M., Jiang, F., Kim, H. J., Dewitt, M. A., Mackley, V. A., Chang, K., Rao, A., Skinner, C., et al. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0137-2 · Cited by 755 · cited 1×
“Gold nanoparticles coupled to DNA and complexed with cationic endosomal disruptive polymers have also been reported to successfully deliver CRISPR RNP to mdx mice (Lee et al., 2017).”
BackgroundCurrent clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Prevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA
Long, C., McAnally, J. R., Shelton, J. M., Mireault, A. A., Bassel-Duby, R., & Olson, E. N. (2014) · Science · doi:10.1126/science.1254445 · Cited by 720
Dystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655 · cited 1×
“It has been shown that viral gene delivery of dystrophin into DMD patients has been associated with an immune response, which limits the expression of dystrophin (Mendell et al., 2010).”
BackgroundVery mild muscular dystrophy associated with the deletion of 46% of dystrophin
England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E. (1990) · Nature · doi:10.1038/343180a0 · Cited by 623 · cited 1×
“In BMD, mutations cause the loss of some exons but do not abolish dystrophin expression, as in the case of DMD (England et al., 1990).”
BackgroundSystemic delivery of genes to striated muscles using adeno-associated viral vectors
Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., Russell, D. W., & Chamberlain, J. S. (2004) · Nature Medicine · doi:10.1038/nm1085 · Cited by 620 · cited 3×
“Numerous truncated dystrophin designs and body-wide systemic viral gene transfer approaches have been investigated in many labs to overcome these barriers (Gregorevic et al., 2004; Odom et al., 2007; Duan, 2016a; Duan, 2018b; Ramos et al., 2019).”
BackgroundMethodQuantitative analysis of the packaging capacity of recombinant adeno-associated virus
Dong, J.-Y., Fan, P.-D., & Frizzell, R. A. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.17-2101 · Cited by 583 · cited 1×
“The currently used recombinant AAVs (rAAV) are erased of all viral genes, specifically the rep and cap genes that encode the nonstructural and structural proteins, and replaced by a sequence of interest, resulting in a maximum encapsidation capacity of around 5 kb (Dong et al., 1996).”
MethodA dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice
Yang, Y., Wang, L., Bell, P., McMenamin, D., He, Z., White, J., Yu, H., Xu, C., Morizono, H., Musunuru, K., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3469 · Cited by 556 · cited 1×
“Hepatocytes and muscle cells have been successfully edited in vivo using a dual-AAV approach (Yang et al., 2016).”
MethodGene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy
Amoasii, L., Hildyard, J. C. W., Li, H., Sanchez-Ortiz, E., Mireault, A., Caballero, D., Harron, R., Stathopoulou, T.-R., Massey, C., Shelton, J. M., et al. (2018) · Science · doi:10.1126/science.aau1549 · Cited by 546 · cited 3×
“Therapeutic effects have been reported in human cells and mice, rats, dogs, and piglets with various DMD mutations (Ousterout et al., 2015; Young et al., 2016; Amoasii et al., 2018; Duchene et al., 2018; Min et al., 2019a; Moretti et al., 2020; Pickar-Oliver et al., 2021; Szabo et al., 2021; Zhang et al., 2021).”
BackgroundMethodMiller, J. B., Zhang, S., Kos, P., Xiong, H., Zhou, K., Perelman, S. S., Zhu, H., & Siegwart, D. J. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201610209 · Cited by 540
A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice
Wehling, M., Spencer, M. J., & Tidball, J. G. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200105110 · Cited by 530
The clinical landscape for AAV gene therapies
Kuzmin, D. A., Shutova, M. V., Johnston, N. R., Smith, O. P., Fedorin, V. V., Kukushkin, Y. S., van der Loo, J. C. M., & Johnstone, E. C. (2021) · Nature Reviews Drug Discovery · doi:10.1038/d41573-021-00017-7 · Cited by 503
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489
Animal models for muscular dystrophy show different patterns of sarcolemmal disruption
Straub, V., Rafael, J. A., Chamberlain, J. S., & Campbell, K. P. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.139.2.375 · Cited by 488
A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy
Wagner, K. R., Fleckenstein, J. L., Amato, A. A., Barohn, R. J., Bushby, K., Escolar, D. M., Flanigan, K. M., Pestronk, A., Tawil, R., Wolfe, G. I., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21338 · Cited by 481
Ousterout, D. G., Kabadi, A. M., Thakore, P. I., Majoros, W. H., Reddy, T. E., & Gersbach, C. A. (2015) · Nature Communications · doi:10.1038/ncomms7244 · Cited by 470
Amin, R. S., Kimball, T. R., Bean, J. A., Jeffries, J. L., Willging, J. P., Cotton, R. T., Witt, S. A., Glascock, B. J., & Daniels, S. R. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2105118 · Cited by 452 · cited 1×
“This process decreases diastolic/systolic function, which plays a role in the atrophy and remodeling that gives rise to heterogeneous pathological alterations to the ventricular myocardium (Amin et al., 2002; Desguerre et al., 2009; Spurney, 2011a; Lee et al., 2014).”
BackgroundMitochondrial reticulum for cellular energy distribution in muscle
Glancy, B., Hartnell, L. M., Malide, D., Yu, Z.-X., Combs, C. A., Connelly, P. S., Subramaniam, S., & Balaban, R. S. (2015) · Nature · doi:10.1038/nature14614 · Cited by 450 · cited 1×
“Within the muscle fiber, mitochondria form a reticular network that surrounds the contractile apparatus, providing a short distance for the ATP supply within the healthy muscle (Glancy et al., 2015).”
BackgroundAndrade, F. H., Reid, M. B., Allen, D. G., & Westerblad, H. (1998) · The Journal of Physiology · doi:10.1111/j.1469-7793.1998.565bn.x · Cited by 438
Mendell, J. R., Sahenk, Z., Lehman, K., Nease, C., Lowes, L. P., Miller, N. F., Iammarino, M. A., Alfano, L. N., Nicholl, A., Al-Zaidy, S., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1484 · Cited by 405
Genetic Fate of Recombinant Adeno-Associated Virus Vector Genomes in Muscle
Schnepp, B. C., Clark, K. R., Klemanski, D. L., Pacak, C. A., & Johnson, P. R. (2003) · Journal of Virology · doi:10.1128/jvi.77.6.3495-3504.2003 · Cited by 262
Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy
Amoasii, L., Long, C., Li, H., Mireault, A. A., Shelton, J. M., Sanchez-Ortiz, E., McAnally, J. R., Bhattacharyya, S., Schmidt, F., Grimm, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan8081 · Cited by 247
Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy
Le Guiner, C., Servais, L., Montus, M., Larcher, T., Fraysse, B., Moullec, S., Allais, M., François, V., Dutilleul, M., Malerba, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms16105 · Cited by 246
Salva, M. Z., Himeda, C. L., Tai, P. W., Nishiuchi, E., Gregorevic, P., Allen, J. M., Finn, E. E., Nguyen, Q. G., Blankinship, M. J., Meuse, L., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300027 · Cited by 232 · cited 2×
“gov: NCT03375164) (Figure 1) (Table 2) (Harper et al., 2002; Salva et al., 2007).”
Precision genome editing using cytosine and adenine base editors in mammalian cells
Huang, T. P., Newby, G. A., & Liu, D. R. (2021) · Nature Protocols · doi:10.1038/s41596-020-00450-9 · Cited by 175 · cited 1×
“In this strategy, Cas9 nickase (nCas9) or deactivated Cas9 (dCas9) is fused to a cytidine deaminase or an engineered adenine deaminase protein, allowing precise single-base pair conversations without double-stranded breaks (Gaudelli et al., 2017; Huang et al., 2021).”
BackgroundCerletti, M., Negri, T., Cozzi, F., Colpo, R., Andreetta, F., Croci, D., Davies, K. E., Cornelio, F., Pozza, O., Karpati, G., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301941 · Cited by 126
Spell Checking Nature: Versatility of CRISPR/Cas9 for Developing Treatments for Inherited Disorders
Wojtal, D., Kemaladewi, D. U., Malam, Z., Abdullah, S., Wong, T. W. Y., Hyatt, E., Baghestani, Z., Pereira, S., Stavropoulos, J., Mouly, V., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.11.012 · Cited by 121
Foster, H., Sharp, P. S., Athanasopoulos, T., Trollet, C., Graham, I. R., Foster, K., Wells, D. J., & Dickson, G. (2008) · Molecular Therapy · doi:10.1038/mt.2008.186 · Cited by 119
Ma, N., Chen, D., Lee, J.-H., Kuri, P., Hernandez, E. B., Kocan, J., Mahmood, H., Tichy, E. D., Rompolas, P., & Mourkioti, F. (2022) · Science Advances · doi:10.1126/sciadv.abn0485 · Cited by 118 · cited 1×
“However, skeletal muscle fibers have a remarkable regeneration capacity (Ma et al., 2022).”
BackgroundFull-Length Dystrophin Reconstitution with Adeno-Associated Viral Vectors
Lostal, W., Kodippili, K., Yue, Y., & Duan, D. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.210 · Cited by 77
Cited by
Giovarelli, M., Zecchini, S., Casati, S. R., Lociuro, L., Gjana, O., Mollica, L., Pisanu, E., Mbissam, H. D., Cappellari, O., De Santis, C., et al. (2025) · Cell Death & Disease · doi:10.1038/s41419-025-07595-z · Cited by 12
Metadata
- Authors
- Bez Batti Angulski, A., Hosny, N., Cohen, H., Martin, A. A., Hahn, D., Bauer, J., & Metzger, J. M.
- Venue
- Frontiers in Physiology
- Publisher
- Frontiers Media SA
- Published
- 2023-06-26
- Volume
- 14
- Pages
- 1183101-1183101
- ISSN
- 1664-042X (ISSN-L)
- OpenAlex
- W4382069925
- Cited by
- 173
- References
- 57
- FWCI
- 12.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.